Sector: Healthcare | Industry: Advanced Medical Equipment & Technology |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 101 GLACIER POINT, SUITE A SAN RAFAEL CA 94901 |
Tel: | 1-212-8671768 |
Website: | https://ir.eksobionics.com |
IR: | See website |
Key People | ||
Scott G. Davis Chief Executive Officer, Director | Jerome Wong Chief Financial Officer, Corporate Secretary | Jason C. Jones Chief Operating Officer |
Business Overview |
Ekso Bionics Holdings, Inc. designs, develops, and markets exoskeleton products. Its exoskeleton technology serves multiple markets and can be utilized both by able-bodied persons and persons with physical disabilities or impairments. Its products include EksoNR, which is a wearable robotic exoskeleton specifically designed to be used in a rehabilitation setting; Ekso Indego Therapy is a modular, adjustable, lightweight, lower-limb powered exoskeleton; Ekso Indego Personal is a lightweight powered lower limb orthosis; Ekso Nomad is a power Knee Ankle Foot Orthosis, and Ekso EVO is a wearable upper body exoskeleton. The Company enables individuals with neurological conditions affecting gait, including acquired brain injury (ABI) and spinal cord injury (SCI), to rehabilitate and to walk again; assist individuals with a range of upper extremity impairments and allow industrial workers to perform difficult repetitive work for extended periods. Its segments include EksoHealth and EksoWorks. |
Financial Overview |
For the fiscal year ended 31 December 2023, Ekso Bionics Holdings Inc revenues increased 42% to $18.3M. Net loss increased 1% to $15.2M. Revenues reflect EksoHealth segment increase of 50% to $17.7M, United States segment increase of 91% to $12.5M, Other Americas segment increase of 96% to $495K. Higher net loss reflects FV Adjustments of Financial Investments decrease from $1.3M (income) to $133K (expense). |
Employees: | 70 as of Mar 1, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $19.11M as of Dec 31, 2023 |
Annual revenue (TTM): | $18.28M as of Dec 31, 2023 |
EBITDA (TTM): | -$13.41M as of Dec 31, 2023 |
Net annual income (TTM): | -$15.20M as of Dec 31, 2023 |
Free cash flow (TTM): | -$12.21M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 17,903,128 as of Mar 1, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |